Calidi Biotherapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
CLDI$0.68-6.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| (Unaudited) | ||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(18,061) | $(20,987) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 304 | 293 |
| Amortization of right of use assets | 838 | 599 |
| Amortization of debt discount and financing costs | 41 | 711 |
| Stock-based compensation | 2,331 | 3,623 |
| Change in fair value of debt, other liabilities and derivatives | (276) | 43 |
| Series B preferred stock financing costs | — | 2,680 |
| Debt extinguishment | — | 471 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 2,050 | (1,867) |
| Accounts payable | 537 | (7,655) |
| Accrued expenses and other current liabilities | (1,285) | 697 |
| Operating lease right of use liability | (750) | (405) |
| Net cash used in operating activities | (14,271) | (21,797) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of machinery and equipment | (11) | (515) |
| Cash assumed in connection with the FLAG Merger | — | 9 |
| Security deposits | — | 63 |
| Net cash used in investing activities | (11) | (443) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from April Public Offering | 5,406 | — |
| Proceeds from May Inducement Offer | 2,140 | — |
| Proceeds from exercise of common stock warrants | 2,835 | — |
| Proceeds from issuance of noncontrolling interest in Nova Cell | 2,000 | — |
| Proceeds from issuance of convertible notes payable | 3,000 | — |
| Proceeds from issuance of common shares and warrants per subscription agreement | 1,000 | — |
| Proceeds from issuance of promissory note | 600 | — |
| Proceeds from exercise of pre-funded warrants | 2 | — |
| Proceeds from exercise of stock options | — | 281 |
| Proceeds from issuance of Series B preferred stock | — | 9,590 |
| Related party proceeds from issuance of Series B preferred stock | — | 14,907 |
| Proceeds from Non-Redemption and PIPE Agreements | — | 2,763 |
| Related party proceeds from issuance of loan payable | 200 | — |
| Proceeds from simple agreements for future equity (SAFE) | — | 2,760 |
| Proceeds from issuance of term notes payable | — | 1,250 |
| Related party proceeds from issuance of term notes payable | — | 2,000 |
| Repayment of financing lease obligations | (63) | (53) |
| Repayment of convertible note payable | (1,500) | — |
| Repayment of term notes payable | (300) | — |
| Payment of debt issuance costs | (9) | — |
| Payment of financing costs | (1,052) | (1,496) |
| Net cash provided by financing activities | 14,259 | 32,002 |
| Effect of exchange rate changes on cash | (29) | 13 |
| NET (DECREASE) INCREASE IN CASH AND RESTRICTED CASH | (52) | 9,775 |
| CASH AND RESTRICTED CASH BALANCE: | ||
| At beginning of the period | 2,167 | 590 |
| At end of the period | $2,115 | $10,365 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||
| Cash paid for interest | $124 | $34 |
| Cash paid for income taxes | $10 | $11 |
| SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES | ||
| Issuance of common stock in lieu of cash for services | $311 | $344 |
| Issuance of common stock in lieu of cash for SEPA commitment fee | $81 | $— |
| Issuance of warrants for deferred compensation settlement in connection with FLAG Merger | $158 | $705 |
| Issuance of common stock for legal settlement | 150 | — |
| Issuance of convertible note for legal settlement | $1,500 | $— |
| Financing fees included in accounts payable and accrued liabilities | $289 | $— |
| Discount on convertible note payable | $149 | $— |
| Deemed dividend on warrants | $1,671 | $— |
| Issuance of common stock per conversion of convertible note | $1,239 | $— |
| Issuance of RSUs for liability settlement | $105 | $— |
| Issuance of common stock with term notes as interest paid in kind and other | $— | $272 |
| Assumed liabilities from FLAG Merger | $— | $(6,808) |
| Assumed warrant liability from FLAG Merger | $— | $(3,389) |
| Issuance of common stock as a result of the FLAG Merger | $— | $56,090 |
| Forward purchase agreement derivative asset | $— | $4,520 |
| Deferred financing fees in connection with FLAG Merger | $— | $(2,604) |
| Issuance of common stock upon conversion of convertible preferred stock | $— | $9,601 |
| Issuance of SAFE in lieu of cash for services | $— | $166 |
| Issuance of common stock for Calidi debt settlement in connection with FLAG Merger | $— | $2,234 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.